Falsifikovanje lekova i medicinskih sredstava – opravdanost i karakteristike krivično-pravne reakcije

XXI vek – Usluge i prava korisnika (2020) str. 741-761

AUTOR(I): Snežana Soković

Download Full Pdf

DOI: 10.46793/UPK20.741S

SAŽETAK:

U aktivnostima suzbijanja falsifikovanih medicinskih proizvoda preklapaju se interesi i intervencije različitih grana privatnog i javnog prava, prava intelektualne svojine, medicinskog prava zaštite javnog zdravlja i krivičnog prava. Obzirom da se akcije suzbijanja falsifikovanih lekova neretko svode na zaštitu komercijalnih interesa i na sudski postupak utvrđivanja prava na naknadu štete, a manje na zaštitu interesa javnog zdravlja i na postupak krivičnopravne intervencije, u radu se razmatra legitimitet krivičnopravnih mera u suzbijanju falsifikovanja medicinskih proizvoda. Cilj rada je da ukaže na ulogu i mehanizme krivičnog prava u globalnom sistemu suzbijanju falsifikovanja medicinskih proizvoda, imajući u vidu da je RSrbija prošle godine potpisala Konvenciju SE o falsifikovanju medicinskih proizvoda i sličnim zločinima koji uključuju pretnju javnom zdravlju (MediCrime konvencija). Nakon analize obima i posledica falsifikovanja medicinskih proizvoda i problema u suzbijanju ove pojave, dolazi se do zaključka da legitimnost krivičnopravne intervencije opravdava evidentno „pandemijsko“ širenje tržišta lažnih lekova i gotovo potpuni nedostatak inkriminacije falsifikovanja lekova u nacionalnim zakonodavstvima. U radu je prikazan sistem krivičnopravnih mera koje ustanovljava Konvencija i analizairan odnos substandardnih, neregistrovanih i generičkih lekova u odnosu kategoriju falsifikovanih lekova definisanih Konvencijom.

KLJUČNE REČI: 

falsifikovni lekovi, krivičnopravna intervencija, MediCrime, konvencija, substandardni lekovi, nergistrovani lekovi.

LITERATURA:

  • Acri, M. L. K., Pharmaceutical Counterfeiting: Endangering, Public Health, Society, and the Economy, Fraser Institute, 2018.
  • Appendix 3 to Annex, World Health Assembly document A70/23, 2017.
  • Attaran, A., Stopping murder by medicine: introducing the Model Law on Medicine Crime, The American Journal of Tropical medicine and hygiene, 2015; 92/6.
  • Attaran, A. et al., How to Achieve International Action on Falsified and Substandard Medicines, British Medical Journal (clinical research ed.) 2012; 345:e7381.
  • Bale, Jr, H. E., The conflicts between parallel trade and product access and innovation: the case of pharmaceuticals. Journal of International Economic Law, 1998; 1(4).
  • Bate, R., Attaran, R., A counterfeit drug treaty: great idea, wrong implementation, Lancet, 2010; 376/9751.
  • Blackstone, E., Fuhr, J. P., Pociask, S., The Health and Economic Effects of Counterfeit Drugs, American Health & Drug Benefits, 2014; 7/4.
  • Venhuis, B. et alt., Oncology drugs in the crosshairs of pharmaceutical crime, The Lancet, 2018, Vol. 19/4.
  • Venhuis, B. J., Identification of health damage caused by Medicrime products in Europe, RIVM Report 040003001, 2013.
  • Guerin, P. J, Singh-Phulgenda, S, Strub-Wourgaft, N., The consequence of COVID-19 on the global supply of medical products: why Indian generics matter for the world; F1000Res. 2020.
  • Dally, A., Thalidomide: was the tragedy preventable? The Lancet, 1998; 351(9110).
  • Directive 2011/62/EU of the European Parliament and of the Council of 8 June 2011 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use, as regards the prevention of the entry into the legal supply chain of falsified medicinal products, Official Journal of the European Union, L 174/74.
  • Explanatory Report to the Council of Europe Convention on the counterfeiting of medical products and similar crimes involving threats to public health, Council of Europe Treaty Series – No. 211.
  • Johnston, A, Holt, D. W., Substandard drugs: a potential crisis for public health, Britsh Journal of Clinical Pharmacology, 2014;78(2).
  • Kennedy, A. Y. P., Petlakh Suny, K., Preliminary Investigation of Pharmaceutical Counterfeiters in the United States, Journal of Qualiative Criminal Justice &Criminology, 2018; 7/1.
  • Kohli, V. P., Combatting Falsification and Counterfeiting of Medicinal Products in the European Union– A Legal Analysis, Copenhagen, 2019.
  • Koscwara, A. K., Dressman, A., Poor-Quality and Counterfeit Drugs: A Systematic Assessment of Prevalence and Risks Based on Data Published From 2007 to 2016, Journal of Pharmaceutical Sciences, 2017; 106/10.
  • Cohen, L. E., Felson, M., SocialChangeandCrimeRateTrends: A Routine Activity Approach American Sociological Review, 1979, 44/4.
  • Council of Europe Convention on the counterfeiting of medical products and similar crimes involving threats to public health, (MediCrime Convention); Council of Europe Treaty Series – No. 211, 2011.
  • Lybecker, K., Illicit trade in counterfeit medicines, in OECD, Illicit Trade: Converging Criminal Networks, Paris, 2010.
  • Mackey, TK., Liang, B.A., Kubic, T., Counterfeit drug penetration into global legitimate medicine supplay chains: a global assessment, The American Journal of Tropical medicine and hygiene, 2015; 92/6.
  • MEDICRIME VS VOLCANO: A practical case study on how the Council of Europe Convention could improve the fight against pharmaceutical crime, (Di Giorgio, D, Russo, D. coord.) Council of Europe, 2019.
  • Mujović Zornić, H., Regulisanje pacijentovih prava u vezi sa korišćenjem lekova, Pravni život, 9/2002.
  • Nayyar, G.M.L. at al., Falsified and Substandard Drugs: Stopping the Pandemic, The American Journal of Tropical medicine and hygiene, 2019;100/5.
  • O’Hagan, A, Garlington, A., Counterfeit drugs and the online pharmaceutical trade, a threat to public safety. Forensic Research & Criminology International Journal. 2018;6(3).
  • Permanand, G., EU pharmaceutical regulation: the politics of policy-making. Manchester, 2006.
  • Planojević, N., Tijanić, M., Otkrivanje lažnih lekova kao preduslov zaštite žiga, Zbornik radova: Pravne i infrastrukturne osnove za razvoj ekonomije zasnovane na znanju, Kragujevac, 2013.
  • Pletier-Rivest, D., Pacini, C., Detecting counterfeit pharmaceutical drugs: A multi-stakeholder forensic accounting strategy, Journal of Financial Crime, 2019; 26/4.
  • Smolka, K., Gronwald, K., Operation PANAGEA – weltweit im Kampf gegen die grenzueberschreitende Arzneikriminalitaet, Bundesgesundheitsbl, 2017/60.
  • Southwick, N., Counterfeit drugs kill 1 mn people annually: Interpol,InSIghtCrime, 2013.
  • Stojanović, Z., Krivično pravo, Beograd, 2019.
  • The European regulatory system for medicines, A consistent approach to medicines regulation across the European Union;EMA/716925/2016, 2017.
  • Transforming our World: The 2030 Agenda for Sustainable Development, A/RES/70/1. UNICRI, Counterfeit Medicines and Organised Crime, 2012.
  • Hall, A., Koenraadt, R., Antonopoulos, G. A., Illicit pharmaceutical networks in Europe: organisingtheillicitmedicinemarketintheUnitedKingdomandtheNetherlands, Trends in Organized Crime 2017/20.
  • Hamilton, W. L. et alt., Public health interventions to protect against falsified medicines: a systematic review of international, national and local policies, Health Policy and Planning, 31/10, 2016.
  • Harris, J., Stivens, P., Morris, J., Keeping it real: Combating the spread of fake drugs in poor countries, Health Issue, International Policy Network, 2009.
  • Qureshi, Z. P. et al., Caveat oncologist: clinical findings and consequences of distributing counterfeit erythropoietin in the United States. Journal of Oncol Practice, 2012; 8(2).
  • WHO Global Surveillance and Monitoring System for Substandard and Falsified medical product, WHO, Geneva, 2017.
  • WHO. Appendix 3, WHO Member State Mechanism on substandard/ spurious/ falsely labelled/counterfeit (SSFFC) medical products working definitions, WHO, Geneva, 2012.
  • https://www.interpol.int/en/News-and-Events/News/2020/Global-operation-sees-a-rise-in-fake-medical-products-related-to-COVID-19
  • https://www.coe.int/en/web/conventions/full-list/-/conventions/treaty/211/signatures
  • https://www.insightcrime.org/news-briefs/counterfeit-drugs-kill-1-millionannually-interpohttps://f1000research.com/articles/9-225
  • http://fraserinstitute.org/studies/pharmaceutical-counterfeiting-endangering-public-health-society-and-the-economy
  • https://policynetwork.blogs.com/fightingdiseases/2009/05/combatting-the-spread-of-fake-drugs-in-poor-countries.html